Human adrenocortical carcinoma cell lines

Molecular and Cellular Endocrinology

Volumn 351, Issue 1, 2012, Pages 58-65

  Wang, Tao ^a   Rainey, William E ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Adrenal cortex; Adrenocortical cell line; Cancer therapy; Cell lines; Model systems; Steroidogenesis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; AMINOGLUTETHIMIDE; ANDROGEN; ETOMIDATE; GLUCOCORTICOID; MELANOCORTIN 2 RECEPTOR; METYRAPONE; MINERALOCORTICOID; MITOTANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SURAMIN;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL CULTURE; CARCINOGENESIS; CCNB2 GENE; CELL CYCLE REGULATION; CELL ISOLATION; CELL LINEAGE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN ACT 1; CELL STRAIN CAR47; CELL STRAIN NCI H295; CELL STRAIN RL 251; CELL STRAIN SW13; CYP11A1 GENE; CYP11B1 GENE; CYP11B2 GENE; CYP17 GENE; CYP21 GENE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; HTR2B GENE; HUMAN; IL13RA2 GENE; IN VITRO STUDY; MARKER GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RARRES2 GENE; REVIEW; SLC16A9 GENE; STEROIDOGENESIS;

ADENOMA; ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ANDROGENS; CELL LINE, TUMOR; GLUCOCORTICOIDS; HUMANS; MINERALOCORTICOIDS; MODELS, BIOLOGICAL;

EID: 84857120661     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.041     Document Type: Review

References (74)

1. Almeida M.Q., Stratakis C.A. How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?. Molecular and Cellular Endocrinology 2011, 336:162-168.
2. Almeida M.Q., Fragoso M.C., Lotfi C.F., Santos M.G., Nishi M.Y., Costa M.H., Lerario A.M., Maciel C.C., Mattos G.E., Jorge A.A., Mendonca B.B., Latronico A.C. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2008, 93:3524-3531.
3. Bandulik S., Penton D., Barhanin J., Warth R. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Hormone and Metabolic Research 2010, 42:450-457.
4. Barlaskar F.M., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G., Giordano T.J., Ben-Josef E., Hammer G.D. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2009, 94:204-212.
5. Bertagna X. Adrenal cortical carcinoma: recent advances in diagnosis and clinical management. Acta Endocrinologica-Bucharest 2010, 6:237-250.
6. Betz M.J., Shapiro I., Fassnacht M., Hahner S., Reincke M., Beuschlein F. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. Journal of Clinical Endocrinology and Metabolism 2005, 90:3886-3896.
7. Bird I.M., Mason J.I., Rainey W.E. Regulation of type 1 angiotensin II receptor messenger ribonucleic acid expression in human adrenocortical carcinoma H295 cells. Endocrinology 1994, 134:2468-2474.
8. Bird I.M., Mason J.I., Rainey W.E. Hormonal regulation of angiotensin II type 1 receptor expression and AT1-R mRNA levels in human adrenocortical cells. Endocrine Research 1995, 21:169-182.
9. Bird I.M., Mason J.I., Oka K., Rainey W.E. Angiotensin-II stimulates an increase in cAMP and expression of 17 alpha-hydroxylase cytochrome P450 in fetal bovine adrenocortical cells. Endocrinology 1993, 132:932-934.
10. Bird I.M., Pasquarette M.M., Rainey W.E., Mason J.I. Differential control of 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. Journal of Clinical Endocrinology and Metabolism 1996, 81:2171-2178.
11. Bird I.M., Word R.A., Clyne C., Mason J.I., Rainey W.E. Potassium negatively regulates angiotensin II type 1 receptor expression in human adrenocortical H295R cells. Hypertension 1995, 25:1129-1134.
12. Bird I.M., Hanley N.A., Word R.A., Mathis J.M., McCarthy J.L., Mason J.I., Rainey W.E. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 1993, 133:1555-1561.
13. Bodrogi I. Third-line chemotherapy of resistant advanced testicular cancer. Progress in Clinical and Biological Research 1989, 303:749-758.
14. Butler R., Robertson J., Gallo J.M. Mutually exclusive expression of beta(III)-tubulin and vimentin in adrenal cortex carcinoma SW13 cells. FEBS Letters 2000, 470:198-202.
15. Cardoso C.C., Bornstein S.R., Hornsby P.J. New methods for investigating experimental human adrenal tumorigenesis. Molecular and Cellular Endocrinology 2009, 300:175-179.
16. Cerquetti L., Sampaoli C., Amendola D., Bucci B., Misiti S., Raza G., De Paula U., Marchese R., Brunetti E., Toscano V., Stigliano A. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G(2) arrest and mismatch repair enzymes modulation. International Journal of Oncology 2010, 37:493-501.
17. Cerquetti L., Sampaoli C., Amendola D., Bucci B., Masuelli L., Marchese R., Misiti S., De Venanzi A., Poggi M., Toscano V., Stigliano A. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Experimental Cell Research 2011, 317:1397-1410.
18. Chen M., Hornsby P.J. Adenovirus-delivered DKK3/WNT4 and steroidogenesis in primary cultures of adrenocortical cells. Hormone and Metabolic Research 2006, 38:549-555.
19. Cheng C.Y., Flasch M.V., Hornsby P.J. Expression of 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in fetal human adrenocortical cells transfected with SV40 T antigen. Journal of Molecular Endocrinology 1992, 9:7-17.
20. Clark B.J., Soo S.C., Caron K.M., Ikeda Y., Parker K.L., Stocco D.M. Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Molecular Endocrinology 1995, 9:1346-1355.
21. de Reynies A., Assie G., Rickman D.S., Tissier F., Groussin L., Rene-Corail F., Dousset B., Bertagna X., Clauser E., Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 2009, 27:1108-1115.
22. Denner K., Rainey W.E., Pezzi V., Bird I.M., Bernhardt R., Mathis J.M. Differential regulation of 11 beta-hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Molecular and Cellular Endocrinology 1996, 121:87-91.
23. Doghman M., Cazareth J., Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism 2008, 93:3222-3225.
24. Fallo F., Pilon C., Barzon L., Pistorello M., Pagotto U., Altavilla G., Boscaro M., Sonino N. Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Endocrine Research 1996, 22:709-715.
25. Fallo F., Pilon C., Barzon L., Pistorello M., Pagotto U., Altavilla G., Boscaro M., Sonino N. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 1998, 44:129-134.
26. Fassnacht M., Libe R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nature Reviews. Endocrinology 2011, 71:323-335.
27. Fassnacht M., Hahner S., Beuschlein F., Klink A., Reincke M., Allolio B. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European Journal of Clinical Investigation 2000, 30(Suppl. 3):76-82.
28. Fernandez-Ranvier G.G., Weng J., Yeh R.F., Khanafshar E., Suh I., Barker C., Duh Q.Y., Clark O.H., Kebebew E. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery 2008, 143:841-846. discussion 846.
29. Fisher R.I., Terry W.D., Hodes R.J., Rosenberg S.A., Makuch R., Gordon H.G., Fisher S.G. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the national cancer institute randomized clinical trial. Surgical Clinics of North America 1981, 61:1267-1277.
30. Gazdar A.F., Oie H.K., Shackleton C.H., Chen T.R., Triche T.J., Myers C.E., Chrousos G.P., Brennan M.F., Stein C.A., La Rocca R.V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Research 1990, 50:5488-5496.
31. Ghorab Z., Jorda M., Ganjei P., Nadji M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Applied Immunohistochemistry & Molecular Morphology 2003, 11:330-333.
32. Giordano T.J., Kuick R., Else T., Gauger P.G., Vinco M., Bauersfeld J., Sanders D., Thomas D.G., Doherty G., Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research 2009, 15:668-676.
33. Hedberg K.K., Chen L.B. Absence of intermediate filaments in a human adrenal cortex carcinoma-derived cell line. Experimental Cell Research 1986, 163:509-517.
34. Hilbers U., Peters J., Bornstein S.R., Correa F.M., Johren O., Saavedra J.M., Ehrhart-Bornstein M. Local renin-angiotensin system is involved in K+-induced aldosterone secretion from human adrenocortical NCI-H295 cells. Hypertension 1999, 33:1025-1030.
35. Hornsby P.J., McAllister J.M. Culturing steroidogenic cells. Methods in Enzymology 1991, 206:371-380.
36. Hornsby P.J., Ryan R.F., Cheng C.Y. Replicative senescence and differentiated gene expression in cultured adrenocortical cells. Experimental Gerontology 1989, 24:539-558.
37. Janes M.E., Chu K.M., Clark A.J., King P.J. Mechanisms of adrenocorticotropin-induced activation of extracellularly regulated kinase 1/2 mitogen-activated protein kinase in the human H295R adrenal cell line. Endocrinology 2008, 149:1898-1905.
38. Kiiveri S., Liu J., Heikkila P., Arola J., Lehtonen E., Voutilainen R., Heikinheimo M. Transcription factors GATA-4 and GATA-6 in human adrenocortical tumors. Endocrine Research 2004, 30:919-923.
39. Kuulasmaa T., Jaaskelainen J., Suppola S., Pietilainen T., Heikkila P., Aaltomaa S., Kosma V.M., Voutilainen R. WNT-4 mRNA expression in human adrenocortical tumors and cultured adrenal cells. Hormone and Metabolic Research 2008, 40:668-673.
40. La Rocca R.V., Stein C.A., Danesi R., Jamis-Dow C.A., Weiss G.H., Myers C.E. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. Journal of Clinical Endocrinology and Metabolism 1990, 71:497-504.
41. Leibovitz A., McCombs W.M., Johnston D., McCoy C.E., Stinson J.C. New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex. Journal of the National Cancer Institute 1973, 51:691-697.
42. McAllister J.M., Hornsby P.J. Improved clonal and nonclonal growth of human, rat and bovine adrenocortical cells in culture. In Vitro Cellular and Developmental Biology 1987, 23:677-685.
43. McAllister J.M., Byrd W., Simpson E.R. The effects of growth factors and phorbol esters on steroid biosynthesis in isolated human theca interna and granulosa-lutein cells in long term culture. Journal of Clinical Endocrinology and Metabolism 1994, 79:106-112.
44. Nesterova M., Bossis I., Wen F., Horvath A., Matyakhina L., Stratakis C.A. An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits. Journal of Clinical Endocrinology and Metabolism 2008, 93:565-571.
45. Nguyen A.D., Conley A.J. Adrenal androgens in humans and nonhuman primates: production, zonation and regulation. Endocrinology Development 2008, 13:33-54.
46. Nogueira E.F., Bollag W.B., Rainey W.E. Angiotensin II regulation of adrenocortical gene transcription. Molecular and Cellular Endocrinology 2009, 302:230-236.
47. Nogueira E.F., Gerry D., Mantero F., Mariniello B., Rainey W.E. The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clinical Endocrinology 2010, 73:22-29.
48. Nogueira E.F., Vargas C.A., Otis M., Gallo-Payet N., Bollag W.B., Rainey W.E. Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells. Journal of Molecular Endocrinology 2007, 39:365-374.
49. Otani H., Otsuka F., Inagaki K., Suzuki J., Miyoshi T., Kano Y., Goto J., Ogura T., Makino H. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008, 149:2816-2825.
50. Parker, K.L., Rainey, W.E., 2004. The Adrenal Gland. In: Text book of Endocrine Physiology, vol. 14, Oxford University Press, New York, pp. 319-348.
51. Parmar J., Key R.E., Rainey W.E. Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. Journal of Clinical Endocrinology and Metabolism 2008, 93:4542-4546.
52. Rainey W.E. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Molecular and Cellular Endocrinology 1999, 151:151-160.
53. Rainey W.E., Bird I.M., Mason J.I. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Molecular and Cellular Endocrinology 1994, 100:45-50.
54. Rainey W.E., Saner K., Schimmer B.P. Adrenocortical cell lines. Molecular and Cellular Endocrinology 2004, 228:23-38.
55. Rainey W.E., Carr B.R., Sasano H., Suzuki T., Mason J.I. Dissecting human adrenal androgen production. Trends in Endocrinology and Metabolism 2002, 13:234-239.
56. Rainey W.E., Bird I.M., Sawetawan C., Hanley N.A., McCarthy J.L., McGee E.A., Wester R., Mason J.I. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. Journal of Clinical Endocrinology and Metabolism 1993, 77:731-737.
57. Rodriguez H., Hum D.W., Staels B., Miller W.L. Transcription of the human genes for cytochrome P450scc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. Journal of Clinical Endocrinology and Metabolism 1997, 82:365-371.
58. Romero D.G., Welsh B.L., Gomez-Sanchez E.P., Yanes L.L., Rilli S., Gomez-Sanchez C.E. Angiotensin II-mediated protein kinase D activation stimulates aldosterone and cortisol secretion in H295R human adrenocortical cells. Endocrinology 2006, 147:6046-6055.
59. Samandari E., Kempna P., Nuoffer J.M., Hofer G., Mullis P.E., Fluck C.E. Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17, 20 lyase activities. Journal of Endocrinology 2007, 195:459-472.
60. Schimmer B.P., Cordova M., Cheng H., Tsao A., Goryachev A.B., Schimmer A.D., Morris Q. Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. Endocrinology 2006, 147:2357-2367.
61. Schteingart D.E., Benitez R., Bradford C., Narayan A., Wang S.M. Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy. Anticancer Research 2010, 30:4805-4809.
62. Schteingart D.E., Giordano T.J., Benitez R.S., Burdick M.D., Starkman M.N., Arenberg D.A., Strieter R.M. Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. Journal of Clinical Endocrinology and Metabolism 2001, 86:3968-3974.
63. Schteingart D.E., Sinsheimer J.E., Counsell R.E., Abrams G.D., Mcclellan N., Djanegara T., Hines J., Ruangwises N., Benitez R., Wotring L.L. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal-cortex and adrenal-cortical carcinoma. Cancer Chemotherapy and Pharmacology 1993, 31:459-466.
64. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer 2006, 6:813-823.
65. Staels B., Hum D.W., Miller W.L. Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. Molecular Endocrinology 1993, 7:423-433.
66. Ueno M., Nakashima J., Akita M., Ban S.I., Nakanoma T., Iida M., Deguchi N. Characterization of a newly established cell line derived from human adrenocortical carcinoma. International Journal of Urology 2001, 8:17-22.
67. Uruno A., Matsuda K., Noguchi N., Yoshikawa T., Kudo M., Satoh F., Rainey W.E., Hui X.G., Akahira J., Nakamura Y., Sasano H., Okamoto H., Ito S., Sugawara A. Peroxisome proliferator-activated receptor-gamma suppresses CYP11B2 expression and aldosterone production. Journal of Molecular Endocrinology 2011, 46:37-49.
68. van Koetsveld P.M., Vitale G., de Herder W.W., Feelders R.A., van der Wansem K., Waaijers M., van Eijck C.H.J., Speel E.J.M., Croze E., van der Lely A.J., Lamberts S.W.J., Hofland L.J. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. Journal of Clinical Endocrinology & Metabolism 2006, 91:4537-4543.
69. Veytsman I., Nieman L., Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology 2009, 27:4619-4629.
70. Vinson G.P. Adrenocortical zonation and ACTH. Microscopy Research and Technique 2003, 61:227-239.
71. Weiss R.B., Charles L.M., Macdonald J.S. M-Amsa - an exciting new drug in the National-Cancer-Institute drug development program. Cancer Clinical Trials 1980, 3:203-209.
72. Xing Y., Edwards M.A., Ahlem C., Kennedy M., Cohen A., Gomez-Sanchez C.E., Rainey W.E. The effects of ACTH on steroid metabolomic profiles in human adrenal cells. Journal of Endocrinology 2011, 209:327-335.
73. Xing Y.W., Parker C.R., Edwards M., Rainey W.E. ACTH is a potent regulator of gene expression in human adrenal cells. Journal of Molecular Endocrinology 2010, 45:59-68.
74. Yamamichi-Nishina M., Ito T., Mizutani T., Yamamichi N., Watanabe H., Iba H. SW13 cells can transition between two distinct subtypes by switching expression of BRG1 and Brm genes at the post-transcriptional level. Journal of Biological Chemistry 2003, 278:7422-7430.